T. Rowe Price Associates’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $232M | Buy |
6,212,681
+857,185
| +16% | +$31.9M | 0.02% | 473 |
|
|
2026
Q1 | $195M | Buy |
5,355,496
+131,109
| +3% | +$5.86M | 0.02% | 467 |
|
|
2025
Q4 | $243M | Sell |
5,224,387
-81,861
| -2% | -$3.64M | 0.03% | 409 |
|
|
2025
Q3 | $221M | Sell |
5,306,248
-284,256
| -5% | -$9.09M | 0.02% | 435 |
|
|
2025
Q2 | $161M | Buy |
5,590,504
+478,144
| +9% | +$14.8M | 0.02% | 480 |
|
|
2025
Q1 | $171M | Sell |
5,112,360
-302,145
| -6% | -$11.3M | 0.02% | 455 |
|
|
2024
Q4 | $277M | Buy |
5,414,505
+469,748
| +9% | +$26.3M | 0.03% | 366 |
|
|
2024
Q3 | $253M | Buy |
4,944,757
+538,301
| +12% | +$27.8M | 0.03% | 391 |
|
|
2024
Q2 | $197M | Buy |
4,406,456
+583,238
| +15% | +$26.9M | 0.02% | 419 |
|
|
2024
Q1 | $179M | Buy |
3,823,218
+814,360
| +27% | +$31.9M | 0.02% | 442 |
|
|
2023
Q4 | $107M | Buy |
3,008,858
+430,659
| +17% | +$13.2M | 0.01% | 529 |
|
|
2023
Q3 | $76.7M | Buy |
2,578,199
+1,149,289
| +80% | +$23.7M | 0.01% | 565 |
|
|
2023
Q2 | $25.8M | Buy |
1,428,910
+1,387,127
| +3,320% | +$27.7M | ﹤0.01% | 871 |
|
|
2023
Q1 | $672K | Sell |
41,783
-10,148
| -20% | -$188K | ﹤0.01% | 1980 |
|
|
2022
Q4 | $951K | Sell |
51,931
-9,704
| -16% | -$171K | ﹤0.01% | 1797 |
|
|
2022
Q3 | $1.21M | Buy |
61,635
+7,228
| +13% | +$147K | ﹤0.01% | 1659 |
|
|
2022
Q2 | $1.01M | Buy |
54,407
+16,824
| +45% | +$336K | ﹤0.01% | 1891 |
|
|
2022
Q1 | $825K | Sell |
37,583
-39,239
| -51% | -$794K | ﹤0.01% | 2096 |
|
|
2021
Q4 | $2.18M | Buy |
76,822
+10,659
| +16% | +$263K | ﹤0.01% | 1680 |
|
|
2021
Q3 | $1.39M | Buy |
66,163
+238
| +0.4% | +$4.98K | ﹤0.01% | 1879 |
|
|
2021
Q2 | $1.24M | Buy |
65,925
+17,060
| +35% | +$300K | ﹤0.01% | 1974 |
|
|
2021
Q1 | $747K | Sell |
48,865
-32,037
| -40% | -$497K | ﹤0.01% | 2187 |
|
|
2020
Q4 | $1.14M | Sell |
80,902
-5,166
| -6% | -$72K | ﹤0.01% | 1879 |
|
|
2020
Q3 | $1.35M | Hold |
86,068
| – | – | ﹤0.01% | 1679 |
|
|
2020
Q2 | $1.51M | Buy |
86,068
+57,660
| +203% | +$983K | ﹤0.01% | 1627 |
|
|
2020
Q1 | $418K | Sell |
28,408
-7,700
| -21% | -$158K | ﹤0.01% | 2060 |
|
|
2019
Q4 | $906K | Sell |
36,108
-16,175
| -31% | -$308K | ﹤0.01% | 1927 |
|
|
2019
Q3 | $786K | Sell |
52,283
-435,633
| -89% | -$8.47M | ﹤0.01% | 1916 |
|
|
2019
Q2 | $12.2M | Buy |
487,916
+1,786
| +0.4% | +$44.2K | ﹤0.01% | 1284 |
|
|
2019
Q1 | $11.1M | Buy |
486,130
+52,134
| +12% | +$1.28M | ﹤0.01% | 1304 |
|
|
2018
Q4 | $13M | Buy |
433,996
+91
| +0% | +$2.56K | ﹤0.01% | 1262 |
|
|
2018
Q3 | $12.4M | Buy |
+433,905
| New | +$12.9M | ﹤0.01% | 1337 |
|
Other funds holding CRNX
FCM
DCM
JT
T. Rowe Price Associates's CRNX Position: Q2 2026 in Review
T. Rowe Price Associates increased its Crinetics Pharmaceuticals (CRNX) stake by 16% in Q2 2026, buying an estimated $31.9M and bringing the position to 6,212,681 shares worth $232M. The position accounts for 0.02% of the portfolio, ranked #473.
T. Rowe Price Associates first reported a position in CRNX in Q3 2018 and has held it in 32 quarters since. The position peaked at $277M in Q4 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.
- T. Rowe Price Associates held 6,212,681 shares of Crinetics Pharmaceuticals worth $232M as of Q2 2026.
- T. Rowe Price Associates bought 857,185 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $31.9M.
- Crinetics Pharmaceuticals made up 0.02% of T. Rowe Price Associates's portfolio in Q2 2026, its #473 holding.
- T. Rowe Price Associates first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
- T. Rowe Price Associates's Crinetics Pharmaceuticals position peaked at $277M in Q4 2024.
- 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.
Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.